Evaluating Urolift to Reduce Urinary Side Effects from Radiation Therapy in Men with BPH and Prostate Cancer
Led by Northwell Health · Updated on 2026-09-29
20
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate whether Urolift, a minimally invasive procedure, can reduce urinary side effects caused by stereotactic body radiation therapy SBRT in male patients with benign prostatic hyperplasia BPH and prostate cancer. These side effects include increased urinary frequency, pain during urination, and nighttime urination. Urolift is already a standard treatment for BPH, designed to keep the prostatic urethra open by placing a stainless-steel implant.
Participants will receive a one-time Urolift procedure before starting SBRT for prostate cancer. Urolift involves placing end pieces on both sides of the prostatic urethra to maintain an open urinary channel. The study involves only one group and includes one year of follow-up after treatment to assess urinary symptoms and quality of life.
During the study, participants will complete questionnaires to measure urinary symptoms and quality of life over an average of one year. Researchers will track changes in urinary symptom scores, sexual function, pain levels, overactive bladder symptoms, and overall health quality. Medication use for urinary symptoms will also be monitored. The study is led by Northwell Health and lasts until March 2028.
CONDITIONS
Brief Title
Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.
Research Team
J
Jennifer Polo, CCRC
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Urolift before SBRT
Current Standard Management (No Urolift before SBRT)
What it is
A minimally invasive device procedure (Urolift) performed before SBRT to address urinary symptoms from BPH in men undergoing radiation for prostate cancer.
Guideline-driven management for BPH typically includes medical therapy (like alpha-blockers or 5-alpha-reductase inhibitors), watchful monitoring, or standard surgical procedures, without routine use of the Urolift device before SBRT for prostate cancer.
Role in the trial
Investigational device procedure; all enrolled participants receive Urolift before SBRT.
Represents how urinary symptoms are typically managed before SBRT for prostate cancer outside the investigational context. This was not directly part of the trial.
Primary use
To reduce urinary symptoms from BPH before prostate cancer radiation and to potentially decrease post-SBRT urinary toxicity.
To control lower urinary tract symptoms by established non-device means. Aim is to manage BPH symptoms before, during, and after prostate cancer radiation, but without specific pre-SBRT mechanical intervention.
How it is given or performed
Urolift procedure is performed in an outpatient setting; recovery typically allows prompt initiation of SBRT.
Medical management usually begins with oral medications; if symptoms persist or medications are unsuitable, more invasive surgery (such as TURP) may be offered.
Evidence maturity or status
Limited to investigational data; direct evidence in patients receiving Urolift before SBRT is not yet available outside ongoing trials.
Supported by robust published evidence and guidelines for managing BPH symptoms in men, including those with prostate cancer undergoing SBRT, though outcomes can vary by method.
Important limitations
Potential limitations include small sample size, lack of direct comparator group, and limited evidence on urinary outcomes following combined Urolift and SBRT treatment.
Medications and standard surgery have established risks (such as sexual dysfunction or incontinence), and symptom improvement may be modest for some men, especially with enlarged prostates or prior pelvic treatment.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 50Years - 99Years
MALE
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Age between 50 and 99 years
Provided informed consent
Diagnosed with prostate cancer requiring stereotactic body radiation therapy (SBRT)
Able to complete self-administered questionnaires
Surgical candidate for Urolift procedure
Diagnosis of benign prostatic hyperplasia (BPH)
Prostate volume between 30 and 80 ml documented by transrectal ultrasound (TRUS)
No presence of a middle lobe
You will not qualify if you...
Life expectancy less than 2 years
Currently enrolled in or planning to enroll in any other drug or device study
Receiving concurrent androgen deprivation therapy
Active infection such as urinary tract infection or prostatitis
Diagnosis or treatment for chronic prostatitis or chronic pelvic pain syndrome
Urethral stricture or bladder neck contracture diagnosed within last 180 days
Two or more urethral strictures and/or bladder neck contractures within 5 years
Diagnosis of lichen sclerosis
Neurogenic bladder or neurological disorder affecting bladder function
Diagnosis of polyneuropathy such as diabetic neuropathy
History of lower urinary tract surgery
Stress urinary incontinence requiring treatment or daily pad/device use
Catheterized or post-void residual volume greater than 400 ml within 14 days prior to surgery
Current diagnosis of bladder stones
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - One-time procedure before SBRT
Participants receive a one-time Urolift procedure before starting stereotactic body radiation therapy (SBRT) for prostate cancer.
Outpatient procedure visit
Follow-up
Duration - One year
Participants complete questionnaires and assessments to monitor urinary symptoms, sexual function, pain, and quality of life for one year after treatment.
Regular follow-up visits during one year
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study of Finasteride Treatment for Benign Prostatic Hyperplasia in Men 50 and Older
Using Gene and MRI Tests to Predict Treatment Response
Study of Lingze Tablets Plus Tamsulosin to Improve Sleep and Nighttime Urination in Men After Prostate Surgery
Study to Test the Safety and Effectiveness of the FloStent Device in Men Over 45 With Benign Prostatic Hyperplasia Symptoms
Study of the Beacon Robot-Assisted Platform for Holmium Laser Surgery in Men with Benign Prostatic Enlargement
Testing a Smart Wearable Electrical Impedance Tomography Device to Monitor Urination in Men with Benign Prostatic Hyperplasia
Safety and Pharmacokinetics Study of AD-116 and AD-1161 in Healthy Adult Men with Benign Prostatic Hyperplasia
Evaluation of the Glean Urodynamics System for Ambulatory Lower Urinary Tract Monitoring in Adults
Comparing Prostate Artery Embolization to Surgery for Treating Enlarged Prostate Symptoms
Randomized Study on Treatment Safety, Recovery, and Quality of Life
International Registry to Collect Data on Treatments and Outcomes for Men with Benign Prostatic Hyperplasia
Randomized Trial Comparing Water Vapour Thermal Therapy Rezum and Prostatic Urethral Lift UroLift for Men With Benign Prostatic Hyperplasia Evaluating Effectiveness and Cost
Prostatic Urethral Lift: A Unique Minimally Invasive Surgical Treatment of Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.